Compare
AIM ImmunoTech Inc. vs VivoSim Labs, Inc. vs Inmune Bio, Inc. vs Entera Bio Ltd.
| Latest fiscal year | AIM ImmunoTech Inc. AIM | VivoSim Labs, Inc. VIVS | Inmune Bio, Inc. INMB | Entera Bio Ltd. ENTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $88.0K | $131.0K | $50.0K | $42.0K |
| Revenue growth (YoY) | -48.2% | -9.0% | +257.1% | -76.8% |
| Gross margin | n/a | n/a | n/a | 0.0% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$13.96M | -$13.84M | -$45.93M | -$11.44M |
| EPS (Diluted) | -$8.62 | -$5.35 | -$1.86 | $0.25 |
| Operating cash flow | -$10.96M | -$10.83M | -$22.58M | -$7.37M |
| Free cash flow | n/a | -$10.83M | -$23.62M | -$7.48M |
| Cash & equivalents | $2.98M | $5.02M | $24.75M | $7.11M |
| Total assets | $5.78M | $7.39M | $32.35M | $15.99M |
| Total liabilities | $15.56M | $8.48M | $8.83M | $2.89M |
| Shareholders' equity | -$9.78M | -$1.10M | $23.52M | $13.10M |
| Return on year-end equity | n/a | n/a | -195.3% | -87.3% |
| Shares outstanding | 3.07M | 2.89M | 26.59M | 46.18M |
Revenue, most recent five fiscal years
| Fiscal year | AIM ImmunoTech Inc. | VivoSim Labs, Inc. | Inmune Bio, Inc. | Entera Bio Ltd. |
|---|---|---|---|---|
| Latest | $88.0K Ended 2025-12-31 | $131.0K Ended 2026-03-31 | $50.0K Ended 2025-12-31 | $42.0K Ended 2025-12-31 |
| 1 year earlier | $170.0K Ended 2024-12-31 | $144.0K Ended 2025-03-31 | $14.0K Ended 2024-12-31 | $181.0K Ended 2024-12-31 |
| 2 years earlier | $202.0K Ended 2023-12-31 | $109.0K Ended 2024-03-31 | $155.0K Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $141.0K Ended 2022-12-31 | $370.0K Ended 2023-03-31 | $374.0K Ended 2022-12-31 | $134.0K Ended 2022-12-31 |
| 4 years earlier | $135.0K Ended 2021-12-31 | $1.50M Ended 2022-03-31 | $181.0K Ended 2021-12-31 | $571.0K Ended 2021-12-31 |